FNCHQ (FNCHQ) Stock Price & Analysis
FNCHQ (FNCHQ) rose 0.00% to USD 7.45 as of June 10, 2026 at 09:21 UTC, according to Nexqual real-time market data.
FNCHQ last closed at USD 7.45; the session ranged USD 7–7.75 on volume of 600 shares. Market capitalization is $11.96M, with a 52-week range of USD 2–16.1 (PNK). Source: Nexqual, June 10, 2026 at 09:21 UTC.
Key Statistics (as of June 10, 2026 at 09:21 UTC)
| Price | USD 7.45 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 7.45 |
| Open | USD 7.75 |
| Day Range | USD 7 – 7.75 |
| 52-Week Range | USD 2 – 16.1 |
| Volume | 600 shares |
| Market Cap | $11.96M |
| Exchange | PNK |
Technical Analysis (FNCHQ)
Nexqual's technical model rates FNCHQ "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 09:21 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 44.17 (neutral) |
| vs SMA50 | Below (USD 7.85) |
| MACD | -0.18 (negative) |
Analyst Ratings (FNCHQ)
Wall Street analysts rate FNCHQ "None", per Nexqual as of June 10, 2026 at 09:21 UTC.
| Consensus Rating | None |
|---|
Earnings (FNCHQ)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-06-30 | USD -3.83 vs est -4.5 ▲ beat |
| 2023-03-31 | USD -10.73 vs est -2.7 ▼ miss |
| 2022-12-31 | USD -16.75 vs est -10.2 ▼ miss |
| 2022-09-30 | USD -13.23 vs est -13.5 ▲ beat |
Source: Nexqual, June 10, 2026 at 09:21 UTC.
Financials & Fundamentals (FNCHQ)
| Total Revenue | $0 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -67.28% |
| Debt / Equity | 203.88 |
| Current Ratio | 3.87 |
| Total Cash | $16.04M |
| Total Debt | $28.99M |
| Free Cash Flow | $-15.96M |
Source: Nexqual, June 10, 2026 at 09:21 UTC.
Financial Health Score (FNCHQ)
Nexqual rates FNCHQ's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 09:21 UTC.
| Growth | Critical — Revenue -95% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Weak — $16M cash vs $29M debt |
| Cash Flow | Weak — FCF negative: -$16M, burning cash |
| Efficiency | Critical — ROE -67%, ROA -21.9% |
Ownership (FNCHQ)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 1.61M |
| Float | 1.56M |
| Short % of Float | +2.76% |
Source: Nexqual, June 10, 2026 at 09:21 UTC.
Leadership (FNCHQ)
FNCHQ is led by Matthew P. Blischak (age 62), President, Secretary & CEO, per Nexqual as of June 10, 2026 at 09:21 UTC.
| President, Secretary & CEO | Matthew P. Blischak (age 62) |
|---|---|
| Executive Vice President of CMC | James S. Sigler (age 64) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CNTB | Connect Biopharma Holdings Limi | USD 2.12 | ▼ 2.3% |
| DSGN | Design Therapeutics, Inc. | USD 10.55 | ▼ 0.94% |
| NEXI | NexImmune, Inc. | USD 0 | ▲ 0% |
| HOWL | Werewolf Therapeutics, Inc. | USD 0.37 | ▼ 4.46% |
| CGEM | Cullinan Therapeutics, Inc. | USD 13.18 | ▼ 2.44% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 09:21 UTC. This page is informational and not investment advice.